Status:
COMPLETED
A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer
Lead Sponsor:
Translational Drug Development
Collaborating Sponsors:
Scottsdale Healthcare
Stand Up To Cancer
Conditions:
Previously Treated Metastatic Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.
Detailed Description
Following first-line therapy with a gemcitabine based regimen, a significant number of patients will maintain an adequate performance status and be able to tolerate a second-line therapy. A recent pha...
Eligibility Criteria
Inclusion
- metastatic adenocarcinoma of the pancreas
- male or non-pregnant female
- 18 years of age or greater
- one prior therapy for the treatment of metastatic disease
- must start continuation therapy within 9 months of starting first line treatment
- have adequate organ and bone marrow function
- must have a Karnofsky performance status greater than or equal to 70
- one or more metastatic tumors measurable by CT scan and accessible for biopsy
Exclusion
- operable or locally advanced pancreatic cancer
- metastatic tumor that is not amendable to biopsy
- known brain mets unless previously treated and well controlled
- active, uncontrolled bacterial, viral or fungal infections
- known infection with HIV, hepatitis B or hepatitis C
- pregnant or breast-feeding patients
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01196247
Start Date
September 1 2010
End Date
February 1 2012
Last Update
July 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
TGen Clinical Research Services at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258